(Q40096612)

17 September 2017

title

Vaccination of sheep with Maedi-visna virus gag gene and protein, beneficial or harmful? (English)

1 reference

Sigurbjörg Torsteinsdóttir

17 September 2017

author

0 references

author name string

Sigurbjörg Torsteinsdóttir

1

1 reference

17 September 2017

Helga María Carlsdóttir

2

1 reference

17 September 2017

Vilhjálmur Svansson

3

1 reference

17 September 2017

Sigrídur Matthíasdóttir

4

1 reference

17 September 2017

Agnes Helga Martin

5

1 reference

17 September 2017

Gudmundur Pétursson

6

1 reference

17 September 2017

language of work or name

English

0 references

publication date

26 July 2007

1 reference

17 September 2017

number of pages

8

1 reference

inferred from page(s)

published in

Vaccine

1 reference

17 September 2017

volume

25

1 reference

17 September 2017

issue

37-38

1 reference

17 September 2017

page(s)

6713-6720

1 reference

Maedi, a chronic, progressive infection of sheep's lungs

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Visna, a demyelinating transmissible disease of sheep

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Identification and subcellular localization of the Q gene product of visna virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

The open reading frame S of visna virus genome is a trans-activating gene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

The vif gene of maedi-visna virus is essential for infectivity in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

A transcriptional map of visna virus: definition of the second intron structure suggests a rev-like gene product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Visna virus encodes a post-transcriptional regulator of viral structural gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Immune response to maedi-visna virus

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

7 January 2021

Mucosal vaccination with an attenuated maedi-visna virus clone

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Mucosal immunization of sheep with a Maedi-Visna virus (MVV) env DNA vaccine protects against early MVV productive infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Nucleotide sequence and biological properties of a pathogenic proviral molecular clone of neurovirulent visna virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Immune response to recombinant visna virus Gag and Env precursor proteins synthesized in insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Intratracheal inoculation as an efficient route of experimental infection with maedi-visna virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

In vivo and in vitro infection with two different molecular clones of visna virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Pathogenesis of central nervous system lesions in visna: cell-mediated immunity and lymphocyte subsets in blood, brain and cerebrospinal fluid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

An indirect enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to maedi-visna virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Transmission of small ruminant lentiviruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

CD4(+) T-cells are required for the establishment of maedi-visna virus infection in macrophages but not dendritic cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

The effect of post-infection immunization on the severity of experimental visna

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Failure of experimental vaccines to protect against infection with ovine progressive pneumonia (maedi-visna) virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Maedi-visna in sheep: host-virus interactions and utilization as a model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

North American and French caprine arthritis-encephalitis viruses emerge from ovine maedi-visna viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Characterisation of an Irish caprine lentivirus strain--SRLV phylogeny revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Immunization with plasmid DNA expressing the caprine arthritis-encephalitis virus envelope gene: quantitative and qualitative aspects of antibody response to viral surface glycoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Prime-boost vaccination with plasmid DNA encoding caprine-arthritis encephalitis lentivirus env and viral SU suppresses challenge virus and development of arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Vaccination with a T-cell-priming Gag peptide of caprine arthritis encephalitis virus enhances virus replication transiently in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Lessons from the cat: development of vaccines against lentiviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Enhancement after feline immunodeficiency virus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Lymphoid activation: a confounding factor in AIDS vaccine development?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Enhancing antibodies in HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

Priming with tat-deleted caprine arthritis encephalitis virus (CAEV) proviral DNA or live virus protects goats from challenge with pathogenic CAEV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

7 January 2021

Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

7 January 2021

Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

7 January 2021

Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.07.004

7 January 2021

10.1016/J.VACCINE.2007.07.004

Identifiers

DOI

1 reference

17 September 2017

1 reference